Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

My view of ICLUSIG is basically the same as the FDA's. It should not be used as a first or second line.

Iclusig should not be used as a 1st or 2nd line?

Ariad and doctors know about Iclusig better than anybody else. They know about it better than any expert posters including Dew, GA or even Biomaven.

At last Friday's CC, an analyst asked whether the company would hike Iclusig's price due to the narrowed label. The answer was "No" because the company believes the label will be wider.

The company does not rule out the front line according to the CEO. Doctor Berger believes the SAEs are manageable and the solution may be as simple as another medication preventing clots such as an Aspirin.

It seems that Dr. Cortes and Dr. Moslehi agree with the company:

Dr. Javid Moslehi, a co-director of the cardio-oncology program at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, said in an interview that if, for instance, the problems were known to occur because of excessive blood clotting from a cancer drug, then patients could also be given another medication to prevent clots. Or, if the cancer drug were causing plaque to build up in the arteries, patients might be given a statin to try to prevent it.